Tetulomab tetraxetan Lu-177
- Generic Name
- Tetulomab tetraxetan Lu-177
- Drug Type
- Small Molecule
- Chemical Formula
- C30H47N7O10S
- Unique Ingredient Identifier
- 6QU69VIG75
- Background
Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
- Conditions
- Non Hodgkin LymphomaFollicular LymphomaRelapsed Follicular Lymphoma
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Nordic Nanovector
- Target Recruit Count
- 7
- Registration Number
- NCT03806179
- Locations
- 🇨🇿
Klinika Hematoonkologie, Ostrava-, Porubá, Czechia
🇳🇴Oslo University Hospital, Oslo, Norway
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
- Conditions
- Relapsed, Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Nordic Nanovector
- Target Recruit Count
- 18
- Registration Number
- NCT02658968
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
🇺🇸University of California, San Diego (UCSD) - Moores Cancer Center, San Diego, California, United States
🇺🇸University of California, San Francisco (UCSF) - Innovation, Technology & Alliances, San Francisco, California, United States
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Nordic Nanovector
- Registration Number
- NCT02657447
- Locations
- 🇩🇪
Universitätsklinikum Würzburg, Würzburg, Germany
A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
- Conditions
- Follicular LymphomaNon-Hodgkin Lymphoma
- Interventions
- Drug: 40 mg lilotomabDrug: 100 mg/m2 lilotomabDrug: 60 mg/m2 lilotomab
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Nordic Nanovector
- Target Recruit Count
- 191
- Registration Number
- NCT01796171
- Locations
- 🇨🇿
FNsP Ostrava, Ostrava-Poruba, Czechia
🇹🇷Hacettepe University Oncology Hospital, Ankara, Turkey
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.